Zydus Life Q2 Results: Mixed Brokerage Reactions Amid Strong Operational Performance

Zydus Lifesciences reported Q2FY26 earnings with solid bottom-line performance, driven by a stronger-than-expected performance in India. Foreign brokerage Nomura noted a 4% beat in Ebitda and a 34% beat in PAT, while Nuvama Institutional Equities retained its 'Reduce' rating, citing pressure on adjusted earnings. Analysts are mixed on the company's growth outlook, with Nomura reiterating its 'Buy' rating and valuing the company at ₹1,140, while Nuvama sees upside potential in the domestic businesses and future growth levers.